Latest From Cigna Corp.
Annual large employer health benefits survey for 2020 and beyond finds support for government price negotiation and payment through a national fund. Plans to expand point-of-sale rebates and coupon accumulator programs also reported.
AAM, Upsher-Smith, APhA, and Cigna tell US FDA that packaging requirement will increase manufacturing and drug costs, create reimbursement hurdles and reduce access to medicines. Daiichi-Sankyo supports agency's proposal.
Recent mergers between PBMs and insurers should address one long-term strategic objective of pharma – the recognition by payors of the value of biopharmaceutical products in relation to other medical costs.
The total cost of Zolgensma is more than $2m – in line with estimates – or $425,000 annually for five years if payers choose an annuity-like payment plan. Novartis is also negotiating value-based reimbursement agreements for infants treated with the one-time infusion.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Cigna Corp.
- Senior Management
David Cordani, Pres. & CEO
Eric Palmer, EVP & CFO
Alan Muney, MD, CMO, EVP, Total Health & Network
- Contact Info
Phone: (860) 226-6000
900 Cottage Grove Rd.
Bloomfield, CT 06002
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.